jueves, 11 de febrero de 2021

FDA approves lisocabtagene maraleucel for relapsed or refractory large B-cell lymphoma | FDA

FDA approves lisocabtagene maraleucel for relapsed or refractory large B-cell lymphoma | FDA

No hay comentarios:

Publicar un comentario